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Abstract
Purpose: Glycine N-methyltransferase (GNMT) affects genetic stability by regulating the ratio of S-adenosylmethionine to S-
adenosylhomocysteine, by binding to folate, and by interacting with environmental carcinogens. In Taiwanese men, GNMT
was found to be a tumor susceptibility gene for prostate cancer. However, the association of GNMT with prostate cancer risk
in other ethnicities has not been studied. It was recently reported that sarcosine, which is regulated by GNMT, increased
markedly in metastatic prostate cancer. We hereby explored the association of GNMT polymorphisms with prostate cancer
risk in individuals of European descent from the Health Professionals Follow-up Study (HPFS).
Methods: A total of 661 incident prostate cancer cases and 656 controls were identified from HPFS. The GNMT short tandem
repeat polymorphism 1 (STRP1), 4-bp insertion/deletion polymorphisms (INS/DEL) and the single nucleotide polymorphism
rs10948059 were genotyped to test for their association with prostate cancer risk.
Results: The rs10948059 T/T genotype was associated with a 1.62-fold increase in prostate cancer risk (95% confidence
interval (CI): 1.18, 2.22) when compared with the C/C genotype. The STRP1 $16GAs/$16GAs genotype was associated with
decreased risk of prostate cancer when compared with the ,16GAs/,16GAs genotype (odds ratio (OR)=0.68; 95% CI: 0.46,
1.01). INS/DEL was not associated with prostate cancer risk. Haplotypes containing the rs10948059 T allele were significantly
associated with increased prostate cancer risk.
Conclusion: In men of European descent, the GNMT rs10948059 and STRP1 were associated with prostate cancer risk.
Compared to the study conducted in Taiwanese men, the susceptibility GNMT alleles for prostate cancer had a reverse
relationship. This study highlights the differences in allelic frequencies and prostate cancer susceptibility in different
ethnicities.
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Introduction
Glycine N-methyltransferase (GNMT, EC2.1.1.20) is a protein
with multiple functions. It affects genetic stability by regulating the
ratio of S-adenosylmethionine (SAM) to S-adenosylhomocysteine
(SAH), by binding to folate [1,2], and by interacting with
carcinogens such as benzo(a)pyrene and aflatoxin B1. We
previously showed that these interactions altered the liver
detoxification pathway and prevented DNA adduct formation
and subsequent cytotoxicity [3–5]. In addition, GNMT regulates
genes related to detoxification and antioxidation pathways [6]. We
previously generated a Gnmt2/2 mouse model and showed that
Gnmt2/2 mice developed chronic hepatitis and glycogen storage
disease in the liver [7]. The Gnmt2/2 mice were followed till 24
months old and all the female and half of the male mice developed
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May 6, 2014hepatocellular carcinoma (HCC) spontaneously [8]. These find-
ings suggest that GNMT deficiency results in decreased ability in
eradicating endogenous free radicals and xenobiotic compounds
both at the cellular level and in an animal model; and therefore,
homeostasis of GNMT expression is very important for the cellular
defense against both endogenous and exogenous stress.
GNMT is expressed in the liver, pancreas, prostate, and kidney
[9]. In studies conducted in Taiwanese men, GNMT was found to
be a tumor susceptibility gene for HCC [9,10] and prostate cancer
[11]. However, the association of GNMT with prostate cancer in
other races or ethnicities remains unclear. A recent study by
Sreekumar et al. reported that sarcosine (N-methylglycine) — a
differential metabolite regulated by GNMT — increased markedly
in tissue and serum of metastatic prostate cancer and was found in
the urine after digital rectal examination in organ-confined disease
[12]. They showed a stepwise elevation of sarcosine tissue
concentration during prostate cancer progression from benign
prostate to clinically localized prostate cancer to metastatic disease.
GNMT is the enzyme responsible for converting glycine to
sarcosine, and they showed that knockdown of GNMT attenuated
prostate cancer invasion. However, subsequent studies on the role
of sarcosine as a potential biomarker for early prostate cancer
detection failed to see any association between sarcosine concen-
tration in the urine and either tumor grade or tumor stage [13,14],
and studies on the association of serum sarcosine levels and
prostate cancer reported conflicting results [15–17].
The human GNMT gene is located at chromosome 6p12 and
we previously reported that it has 3 polymorphic sites in the
promoter region that may affect transcriptional activity: short
tandem repeat 1 (STRP1), a (GA)n dinucleotide repeat polymor-
phism, INS/DEL with insertion or deletion of a GAGT
tetranucleotide, and rs10948059 [9,11,18]. A recent study in
Italians by Ianni et al. showed that the GNMT rs9462856 T allele,
which is also located in the promoter region upstream of
rs10948059, was associated with increased prostate cancer risk
[19]. Using the publicly available HapMap version 3, release R2
database, strong linkage disequilibrium was found between Ianni
et al.’s rs9462856 and rs10948059 (D9=1.000 and r
2=0.760 in
Utah residents with Northern and Western European ancestry
from the CEPH collection and D9=0.946 and r
2=0.737 in Han
Chinese in Beijing, China). In this study, we tried to determine the
association of the GNMT polymorphisms STRP1, INS/DEL and
rs10948059 and prostate cancer risk in Americans of European
ancestry.
Methods
Study population
In this nested case-control study, incident prostate cancer cases
were identified from the ongoing Health Professionals Follow-up
Study (HPFS) in the United States. In 1986, 51,529 males in
health professions (e.g., dentists, pharmacists, optometrists, oste-
opath physicians, podiatrists, and veterinarians) were enrolled in
HPFS. At baseline, participants completed a questionnaire on
demographics, diseases, and health-related topics. These ques-
tionnaires were repeated every two years. Information on deaths
was obtained from family members, follow-up questionnaires, or a
search of the National Death Index and was conducted through
March 2011 [20].
Between 1993 and 1995, blood samples were obtained from
18,018 participants, collected in EDTA tubes, shipped by
overnight courier, and centrifuged. Aliquots, including plasma,
erythrocytes, and buffy coat, were stored in liquid nitrogen, and
DNA was extracted using a QIAamp blood extraction kit (Qiagen,
Inc., Valencia, CA).
A total of 661 incident prostate cancer cases and 656 controls
were identified from the HPFS for our study between 1993 (time of
blood return) and January 31, 2000. Matching was one-to-one.
Each case was matched with a control that was alive, had not been
diagnosed with cancer by the date of the case’s diagnosis, and had
a prostate specific antigen (PSA) test performed. We restricted the
analysis to individuals of European descent to reduce the potential
for population stratification.
Demographic data recorded from all subjects included age,
body mass index (BMI), and family history of prostate cancer. In
prostate cancer cases, clinicopathological data including PSA level,
Gleason score and disease stage were recorded. Patients were
classified as having aggressive prostate cancer if they had PSA.
20 ng/ml, tumor stage $III or N1 or M1, or Gleason score $8.
Lethal prostate cancer cases were those who had metastases at
diagnosis or who progressed to metastases or prostate cancer
specific death. This study was approved by the Human Subjects
Committee at the Harvard School of Public Health and the
Human Subjects Committee at Brigham and Women’s Hospital.
Written consent was given by the patients for their information to
be stored in the hospital database and used for research.
Genotyping of the GNMT genetic polymorphisms
Three polymorphisms of GNMT were analyzed in this study:
STRP1, INS/DEL and rs10948059. A TaqMan 59 nuclease assay
was used for genotyping of rs10948059, and automated fragment
analysis (GeneScan) was used for genotyping of STRP1 and INS/
DEL. Details of the methods and primers used have been
described previously [18].
Statistical analysis
Genotype frequencies were tested for Hardy-Weinberg equilib-
rium among controls by chi-square test. Odds ratios (OR) and
95% confidence intervals (CI) were computed for the associations
between each genotype with prostate cancer by logistic regression
models adjusted for age at blood draw. Analyses restricted to
prostate cancer subtypes (e.g. aggressive and lethal) used all
controls. We used polytomous logistic regression to assess whether
the associations were different with aggressive and non-aggressive
cancers. The GENECOUNTING software (version 2.0), which
implements an estimation-maximization algorithm, was used to
estimate the haplotype frequencies and to calculate linkage
disequilibrium between the markers [21,22]. Statistical analyses
were done using SAS v9.2 statistical software (SAS Institute, Cary
NC), and 2-sided p-value of,0.05 was considered significant.
Results
Characteristics of the study participants were described in a
previous study [23] and selected characteristics are presented in
Table 1. In summary, the mean age at blood draw in cases and
controls was about 66 years and the mean age at diagnosis in cases
was about 69 years. Fourteen percent of prostate cancer cases and
11 percent of controls had a family history of prostate cancer.
In prostate cancer cases, the median PSA level was 7.0
(interquartile range: 5.2, 10.8), with the majority of patients
(n=445, 67.3%) having an initial PSA level 10 ng/ml or less.
Only 67 (10.1%) cases had a Gleason score between 8 and 10 and
the majority (n=546, 82.6%) of the cases had T1 or T2 disease.
Twenty-four percent (161) of the cases were classified as aggressive
and 11.8% (78) had distant metastases at diagnosis or progressed
to death or metastases.
GNMT and Prostate Cancer Risk in HPFS
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Weinberg equilibrium (p=0.55). There was an increased risk of
total prostate cancer for those with the T/T genotype compared
with the C/C genotype (OR=1.62; 95% CI: 1.18, 2.22) (Table 2).
The relationship was suggestively stronger in non-aggressive cases
(OR=1.81; 95%CI: 1.30, 2.53) when compared with aggressive
cases (OR=1.21; 95%CI: 0.76, 1.92) although the p-heterogene-
ity (0.09) was not statistically significant (Table 3).
STRP1 alleles were categorized into two groups: ,16GAs and
$16GAs. Genotypic frequencies in controls were: 32.8% ,
16GAs/,16GAs, 56.3% ,16GAs/$16GAs, and 11.0% $
16GAs/$16GAs. Subjects with $16GAs/$16GAs had decreased
risk of prostate cancer when compared to those with ,16GAs/,
16GAs (OR=0.68; 95% CI: 0.46, 1.01) (Table 2). This protective
association of $16GAs was consistently seen in non-aggressive,
aggressive and lethal prostate cancers (Table 3).
INS/DEL was not in Hardy-Weinberg equilibrium in controls
(p,0.0001). An association between INS/DEL and prostate
cancer was not seen (Table 2).
Linkage disequilibrium was not strong among the 3 markers. D9
was 0.837 for STRP1-INS/DEL, 0.634 for INS/DEL-
rs10948059, and 0.560 for STRP1-rs10948059. Haplotype
analysis of STRP1-rs10948059 showed that, when compared with
the other haplotypes, haplotypes with the rs10948059 T allele
were significantly associated with increased prostate cancer risk
(OR=1.19, 95%CI: 1.00, 1.42 for 10GAs-T; OR=1.46, 95%CI:
1.02, 2.10 for 16GAs-T), while those with the rs10948059 C allele
tended towards a protective effect against prostate cancer
(OR=0.76, 95%CI: 0.63, 0.92 for 16GAs-C). (Table 4)
Discussion
In our study of men of European descent, GNMT STRP1 and
rs10948059 were indeed associated with prostate cancer risk.
Those with an increased number of tandem repeats ($16GAs/$
16GAs) had a 32% decreased risk of prostate cancer compared to
those with less repeats (,16GAs/,16GAs). In addition, those
with the rs10948059 T/T genotype had a 62% increased risk of
prostate cancer compared to those with the C/C genotype This
association appeared to be stronger in non-aggressive compared
with aggressive cancers. These findings are in agreement with
those of a recent study by Koutros et al., which showed a stronger
Table 1. Characteristics of prostate cases (PCa) and controls.
Cases (n=661) Controls (n=656)
Age at blood draw, mean (sd) 65.8 (7.5) 65.7 (7.4)
Time to PCa diagnosis from blood draw (years), median (IQR) 3.2 (1.7, 4.5)
Age at diagnosis, mean (sd) 68.9 (7.3)
,65 years 180(27.2%)
.=65 years 481(72.8%)
Stage, n (%)*
T1, T2 (N0, M0) 546 (82.6%)
T3a (N0, M0) 51(7.7%)
T3b (N0, M0) 24 (3.6%)
T4 (N0, M0) 0 (0%)
N1 10 (1.5%)
M1 10 (1.5%)
Gleason score, n (%)**
2t o6 337 (51.0%)
7: 3+4 or no major score defined 156 (23.6%)
7: 4+3 70 (10.6%)
8t o1 0 67 (10.1%)
PSA at diagnosis, median (IQR)*** 7.0 (5.2, 10.8)
0t o4 78 (11.8%)
4.1 to 10 367 (55.5%)
10.1 to 20 120 (18.2%)
.20 52 (7.9%)
Aggressive (PSA at diagnosis.20 or
Gleason 8–10 or stage T3 or higher) 161 (24.4%)
Deaths/metastases due to PCa, n (%) 78 (11.8%)
PCa deaths without recorded metastatic date 48
Metastases to bone or organ on follow-up 20
Metastases at diagnosis 10
* 20 missing data on stage (3.0%).
** 31 missing data on Gleason score (4.7%).
*** 44 missing data on PSA at diagnosis (6.7%).
doi:10.1371/journal.pone.0094683.t001
GNMT and Prostate Cancer Risk in HPFS
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cancer, but no association with aggressive prostate cancer [17]. It
is therefore possible that GNMT may be a biomarker for early
non-aggressive prostate cancer.
Our study results are also supported by a study on the genotypic
and phenotypic association of GNMT, which demonstrated that
promoters containing either STRP1 10 GAs (,16 GAs) or
rs10948059 T allele had significantly higher transcriptional
activity than promoters containing STRP1 16 GAs ($16 GAs)
or rs10948059 C allele [18].
Although GNMT acts as a tumor suppressor and was found to
be down-regulated in HCC, its role in the pathogenesis of prostate
cancer remains unknown. Gnmt2/2 mice developed HCC but
not prostate cancer, suggesting that other risk factors contributed
to the tumorigenesis of prostate cancer besides deficiency or
perturbation of the expression level of GNMT. Previously, we used
a yeast two-hybrid system to screen proteins interacting with
GNMT and found that DEPTOR [24] and NPC2 [25] bound
directly with GNMT. We postulate that maybe GNMT exerts its
function by interacting with other effectors including DEPTOR
and NPC2. DEPTOR is an mTOR inhibitor reported to have an
important and more direct role in prostate carcinogenesis [24].
Therefore, further studies on the association of DEPTOR and
NPC2 with prostate cancer are needed.
Findings of this study are in contrast to those of our study in
Taiwanese men, which showed that the rs10948059 T allele was
not significantly associated with non-aggressive prostate cancer
(OR=0.68, 95%CI: 0.36, 1.27) and had a protective association
against aggressive prostate cancer (OR=0.67, 95%CI: 0.47, 0.96)
[11]. The distributions of allelic and genotypic frequencies were
also significantly different between ethnicities (p,0.0001 for all
comparisons). (Table 5) In Taiwanese men, the $16 GAs allele
was more common (63.8%), while in men of European descent,
the ,16 GAs allele was more common (61.0%). The ,16 GAs
allele was not associated with prostate cancer risk in Taiwanese
men, while it was associated with a 23 percent increase in prostate
cancer risk in men of European descent. In Taiwanese men, the ,
16GAs/,16GAs genotype was present in 12% of prostate cancer
cases and 13% of controls, while in the HPFS, it was present in
39% of prostate cancer cases and 33% of controls. These findings
clearly illustrate different allelic and genotypic distributions in
Taiwanese and European American men.
In Taiwanese men, the rs10948059 C allele was significantly
more common than the T allele (85% vs. 15%), while in men of
European descent, the C allele was slightly more common than the
T allele (54% vs. 46%). In Taiwanese men, the rs10948059 T
allele had a protective association against prostate cancer
(OR=0.72). In contrast, in men of European descent, the T
allele was associated with increased prostate cancer risk
(OR=1.27). Therefore, the rs10948059 T allele has opposite
associations in different ethnic groups. This difference further
suggests that it is necessary to validate in a specific ethnicity any
associations seen in other ethnicities. Racial and ethnic variations
in cancer risk may reflect differences in environmental exposure or
differences in susceptibility and biologic response [26]. Polymor-
phic expression of genes may affect, either by activation or
detoxification, the metabolism of carcinogens, such as polycyclic
aromatic hydrocarbons, aromatic amines, heterocyclic amines,
and other factors. In turn, exposure to different environmental
factors may affect the genes and select against specific genetic
polymorphisms. Over time, these gene-environment interactions
may result in the variable effects seen in different races and
ethnicities. It is possible that genes involved in detoxification
pathways may be more susceptible to such influences. Kato et al.
reported opposite associations of Cytochrome P450IIE1 polymor-
phisms with lung cancer risk in European and African Americans
[27]. Moreover, our study showed that polymorphisms of GNMT,
which also participates in detoxification, have variable associations
in men of European descent and Asians.
All of the prostate cancer cases and controls in this study were of
European descent. It is therefore uncertain whether these GNMT
genetic polymorphisms are associated with prostate cancer risk in
Table 2. Frequency of GNMT polymorphisms and association with prostate cancer risk.
Cases n(%) Controls n(%) aOR (95% CI) p-value
rs10948059*
CC 156(25.3) 176(29.0) 1.00 (ref)
CT 283(45.9) 309(50.8) 1.03 (0.79, 1.35) 0.814
TT 177(28.7) 123(20.2) 1.62 (1.18, 2.22) 0.003
per-allele 1.27(1.08–1.48) 0.003
STRP1
,16GAs/,16GAs 247(38.8) 209(32.8) 1.00 (ref)
.=16GAs/,16GAs 332(52.2) 359(56.3) 0.78 (0.61–0.99) 0.039
.=16GAs/.=16GAs 57(9.0) 70(11.0) 0.68 (0.46–1.01) 0.058
per-additional GAs 0.81 (0.68–0.97) 0.019
INS/DEL**
DEL/DEL 77(12.3) 86(13.6) 1.00 (ref)
DEL/INS 415(66.4) 418(66.2) 1.12 (0.80, 1.57) 0.520
INS/INS 133(21.3) 127 (20.1) 1.18 (0.80, 1.75) 0.415
per-additional 4-bp 1.08(0.89–1.31) 0.433
aOR=age-adjusted OR.
*Minor allele frequency in controls=0.456.
**not in HWE.
doi:10.1371/journal.pone.0094683.t002
GNMT and Prostate Cancer Risk in HPFS
PLOS ONE | www.plosone.org 4 May 2014 | Volume 9 | Issue 5 | e94683T
a
b
l
e
3
.
A
n
a
l
y
s
i
s
o
f
p
o
l
y
m
o
r
p
h
i
s
m
s
a
c
c
o
r
d
i
n
g
t
o
p
r
o
s
t
a
t
e
c
a
n
c
e
r
a
g
g
r
e
s
s
i
v
e
n
e
s
s
a
n
d
l
e
t
h
a
l
i
t
y
.
N
o
n
-
a
g
g
r
e
s
s
i
v
e
A
g
g
r
e
s
s
i
v
e
L
e
t
h
a
l
c
a
s
e
s
(
%
)
a
O
R
(
9
5
%
C
I
)
p
-
v
a
l
u
e
c
a
s
e
s
(
%
)
a
O
R
(
9
5
%
C
I
)
p
-
v
a
l
u
e
c
a
s
e
s
(
%
)
a
O
R
(
9
5
%
C
I
)
p
-
v
a
l
u
e
r
s
1
0
9
4
8
0
5
9
*
C
C
9
5
(
2
2
.
6
)
1
.
0
0
(
r
e
f
)
4
5
(
3
0
.
4
)
1
.
0
0
(
r
e
f
)
2
0
(
2
7
.
4
)
1
.
0
0
(
r
e
f
)
C
T
2
0
3
(
4
8
.
2
)
1
.
1
8
(
0
.
8
9
–
1
.
5
7
)
0
.
2
4
6
4
(
4
3
.
2
)
0
.
8
0
(
0
.
5
4
–
1
.
1
8
)
0
.
2
6
3
3
(
4
5
.
2
)
0
.
9
5
(
0
.
5
3
,
1
.
7
2
)
0
.
8
8
T
T
1
2
3
(
2
9
.
2
)
1
.
8
1
(
1
.
3
0
–
2
.
5
3
)
0
.
0
0
0
5
3
9
(
2
6
.
4
)
1
.
2
1
(
0
.
7
6
–
1
.
9
2
)
0
.
4
3
2
0
(
2
7
.
4
)
1
.
4
1
(
0
.
7
2
,
2
.
7
4
)
0
.
3
2
p
e
r
-
a
l
l
e
l
e
1
.
3
6
(
1
.
1
4
–
1
.
6
3
)
0
.
0
0
0
6
1
.
0
9
(
0
.
8
4
–
1
.
4
0
)
0
.
5
2
1
.
1
8
(
0
.
8
4
–
1
.
6
7
)
0
.
3
4
S
T
R
P
1
,
1
6
G
A
s
/
,
1
6
G
A
s
1
6
8
(
3
8
.
7
)
1
.
0
0
(
r
e
f
)
6
4
(
4
0
.
8
)
1
.
0
0
(
r
e
f
)
3
1
(
4
0
.
3
)
1
.
0
0
(
r
e
f
)
.
=
1
6
G
A
s
/
,
1
6
G
A
s
2
2
7
(
5
2
.
3
)
0
.
7
8
(
0
.
6
0
–
1
.
0
1
)
0
.
0
6
8
1
(
5
1
.
6
)
0
.
7
5
(
0
.
5
2
–
1
.
0
7
)
0
.
1
1
4
3
(
5
5
.
8
)
0
.
7
8
(
0
.
4
8
,
1
.
2
9
)
.
=
1
6
G
A
s
/
.
=
1
6
G
A
s
3
9
(
9
.
0
)
0
.
6
8
(
0
.
4
4
–
1
.
0
5
)
0
.
0
8
1
2
(
7
.
6
)
0
.
5
7
(
0
.
2
9
–
1
.
1
2
)
0
.
1
1
3
(
3
.
9
)
0
.
2
8
(
0
.
0
8
,
0
.
9
4
)
p
e
r
-
a
d
d
i
t
i
o
n
a
l
G
A
s
0
.
8
1
(
0
.
6
7
–
0
.
9
9
)
0
.
0
4
0
.
7
4
(
0
.
5
5
–
0
.
9
8
)
0
.
0
4
0
.
6
6
(
0
.
4
4
–
0
.
9
8
)
0
.
0
4
I
N
S
/
D
E
L
*
*
D
E
L
/
D
E
L
5
0
(
1
1
.
6
)
1
.
0
0
(
r
e
f
)
1
9
(
1
2
.
6
)
1
.
0
0
(
r
e
f
)
7
(
9
.
6
)
1
.
0
0
(
r
e
f
)
D
E
L
/
I
N
S
2
8
6
(
6
6
.
5
)
1
.
1
0
(
0
.
7
9
–
1
.
5
4
)
0
.
5
8
1
0
3
(
6
8
.
2
)
0
.
9
2
(
0
.
5
8
–
1
.
4
6
)
0
.
7
2
5
5
(
7
5
.
3
)
1
.
5
4
(
0
.
6
7
,
3
.
5
1
)
0
.
3
1
I
N
S
/
I
N
S
9
4
(
2
1
.
9
)
1
.
1
7
(
0
.
7
8
–
1
.
7
4
)
0
.
4
6
2
9
(
1
9
.
2
)
0
.
8
7
(
0
.
4
9
–
1
.
5
5
)
0
.
6
4
1
1
(
1
5
.
1
)
1
.
0
6
(
0
.
3
9
,
2
.
8
6
)
0
.
3
p
e
r
-
a
d
d
i
t
i
o
n
a
l
4
-
b
p
1
.
1
2
(
0
.
9
1
–
1
.
3
9
)
0
.
2
9
1
.
0
1
(
0
.
7
4
–
1
.
3
8
)
0
.
9
7
0
.
9
7
(
0
.
6
3
–
1
.
5
0
)
0
.
9
0
a
O
R
=
a
g
e
-
a
d
j
u
s
t
e
d
O
R
,
n
u
m
b
e
r
o
f
c
o
n
t
r
o
l
s
=
6
5
6
.
*
M
A
F
i
n
c
o
n
t
r
o
l
s
=
0
.
4
6
.
*
*
n
o
t
i
n
H
W
E
.
p
-
h
e
t
e
r
o
g
e
n
e
i
t
y
b
e
t
w
e
e
n
a
g
g
r
e
s
s
i
v
e
a
n
d
n
o
n
-
a
g
g
r
e
s
s
i
v
e
f
o
r
r
s
1
0
9
4
8
0
5
9
:
C
T
v
s
C
C
=
0
.
0
6
,
T
T
v
s
C
C
=
0
.
0
9
,
p
e
r
-
a
l
l
e
l
e
=
0
.
0
9
.
d
o
i
:
1
0
.
1
3
7
1
/
j
o
u
r
n
a
l
.
p
o
n
e
.
0
0
9
4
6
8
3
.
t
0
0
3
GNMT and Prostate Cancer Risk in HPFS
PLOS ONE | www.plosone.org 5 May 2014 | Volume 9 | Issue 5 | e94683other ethnicities such as African Americans. A study comprising of
50% Mexican American, 18% European American, 18% African
American, 12% Asian and 1% Arab women reported a
rs10948059 T allele frequency of 36.4% [28], which is lower
than the 45.8% reported in this study. Studies in other ethnic
groups, which could all have varying allelic frequencies, are
therefore necessary to clarify these associations.
In our previous study in Taiwanese men comprising of 326 prostate
cancer cases and 327 controls [11], the allelic frequencies were
comparable to those of another study by our group [29]. The
frequencyof the T allele remained constant at around 15% in controls
after pooling subjects from both studies (.600 controls), suggesting
that the allelic frequencies were not affected by sample size.
INS/DEL was excluded from haplotype analysis because it was
not in Hardy-Weinberg equilibrium (p,0.0001). Haplotype
analysis of STRP1-rs10948059 showed that the most common
haplotype was 10GAs-T accounting for 40% of controls and 44%
of cases, followed by 16GAs-C, and 10GAs-C. (Table 4) Haplo-
types with the rs10948059 T allele had ORs greater than 1,
suggesting that presence of the rs10948059 T allele per se
increased susceptibility to prostate cancer. In Taiwanese men,
linkage disequilibrium among the 3 markers was stronger (D9 was
0.988 for STRP1-INS/DEL, 0.948 for INS/DEL-rs10948059,
and 0.945 for STRP1-rs10948059). The 10GAs-INS-T haplotype
was associated with decreased prostate cancer risk in Taiwanese
men (OR=0.68, 95%CI=0.48–0.95).
The strength of this study was that we were able to see the
variable associations of GNMT with prostate cancer in different
ethnicities. A limitation of this study was the lack of data on GNMT
expressionlevels,soacorrelationwithgenotypescouldnotbemade.
Immunohistochemical studies may be performed to further
elucidate the association of GNMT with prostate cancer in these
Table 4. Haplotype frequencies and their association with prostate cancer risk (haplotype STRP1- rs10948059).
Haplotypes* PCa cases** Controls** OR (95% CI) p-value
10GAs-T 44.1% 39.8% 1.19 (1.00–1.42) 0.048
16GAs-C 25.4% 31.0% 0.76 (0.63–0.92) 0.005
10GAs-C 16.6% 18.7% 0.87 (0.69–1.09) 0.212
16GAs-T 7.5% 5.3% 1.46 (1.02–2.10) 0.039
17GAs-C 4.1% 3.9% 1.05 (0.67–1.63) 0.841
*Only haplotypes with estimated frequencies .1% are listed.
**Estimated numbers of informative haplotypes: PCa cases=1034, controls=1003.
doi:10.1371/journal.pone.0094683.t004
Table 5. Frequency of the polymorphisms and association of the risk alleles with prostate cancer in Taiwanese prostate cancer
study and HPFS controls.
Taiwanese prostate cancer
study
7 HPFS p-value*
rs10948059
Allelic frequencies
C:T 0.85:0.15 0.54:0.46 ,0.0001
Genotypic frequencies
C/C:C/T:T/T 0.72:0.25:0.02 0.29:0.51:0.20 ,0.0001
STRP1
Allelic frequencies
$16 GAs:,16 GAs 0.64:0.36 0.39:0.61 ,0.0001
Genotypic frequencies
$16GAs/$16GAs:$16GAs/,16 GAs:,16GAs/,16GAs 0.41:0.46:0.13 0.11:0.56:0.33 ,0.0001
INS/DEL
Allelic frequencies
DEL:INS 0.65:0.35 0.47:0.53 ,0.0001
Genotypic frequencies
DEL/DEL:INS/DEL:INS/INS 0.42:0.46:0.12 0.14:0.66:0.20 ,0.0001
OR (95%CI) OR (95%CI)
rs10948059 (per-additional T allele) 0.72 (0.52–0.99) 1.27 (1.08–1.48)
STRP1 (per-reduced GAs) 1.09 (0.88–1.37) 1.23 (1.03–1.47)
INS/DEL (per-additional 4-bp) 0.89 (0.71–1.12) 1.08 (0.89–1.31)
*Comparison of GNMT allelic and genotypic distributions between Taiwanese population and HPFS (chi-square test).
doi:10.1371/journal.pone.0094683.t005
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PLOS ONE | www.plosone.org 6 May 2014 | Volume 9 | Issue 5 | e94683men of European descent. Immunohistochemical staining using the
GNMT monoclonal antibody 14-1 at 1:25 dilution was previously
performed in prostatic tissues obtained from Taiwanese men and a
tissue array of Asian men [11]. GNMT expression tended to be
higher in non-cancerous than in prostate cancer and tumor-
adjacent tissues; and in the cancer tissues, staining was higher in low
stage than high stage cancers. These findings are in contrast to those
from Song et al.’s study in 148 Japanese men, which showed that
high cytoplasmic GNMT expression was correlated with higher
Gleason score, higher pathological stage, and lower disease-free
survival [30]. While both studies were performed in Asian men,
Song et al. used a polyclonal antibody for immunohistochemical
staining, so there could be specificity issues, and results from both
studies cannot be directly compared. Longitudinal follow-up studies
may help clarify the relationship between GNMT expression and
disease progression and aggressivity.
Finally, it is worth noting that a higher proportion of subjects in
this study had localized (stage I or II) disease (85%) when
compared to our previous Taiwanese study (32%) [11]. The study
in Taiwanese men was hospital-based, while the HPFS is
composed of health care professionals. Health care professionals
are more health-conscious and are more likely to have regular
physical examinations than the general population
. The use of
PSA screening was high in the HPFS.
Conclusions
In men of European descent, the GNMT rs10948059 and
STRP1 were associated with prostate cancer risk. Compared to the
studyconductedinTaiwanesemen,thesusceptibilityGNMT alleles
for prostate cancer had a reverse relationship. This study
demonstrated the importance of validating associations in different
ethnicities, as the allelic and genotypic frequencies were different,
and the resulting associations between markers and prostate cancer
also differed. Results from this study suggest that GNMT plays a
role in prostatic carcinogenesis, but in view of the conflicting results
ofrecentstudies onsarcosine,furtherstudies areneededto elucidate
the role of GNMT in prostate cancer aggressivity.
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